EU Regulator Backs Higher-Dose Wegovy 7.2 mg Pen
Europe's EMA committee recommended marketing authorisation for Wegovy 7.2 mg on May 22, citing 20.7% mean weight loss in the STEP UP trial — the drug's highest-dose form.
May 25, 2026 · 2 min read
Europe's drug regulator has cleared the highest dose of Wegovy for use in adults with obesity. The Committee for Medicinal Products for Human Use (CHMP) — the European Medicines Agency's (EMA) scientific review body — issued a positive opinion on May 22, recommending marketing authorisation for Wegovy 7.2 mg in a single-dose injection pen.
What happened
The CHMP's positive opinion follows the STEP UP clinical trial program, which tested the 7.2 mg dose of semaglutide in adults with obesity. The trial reported mean weight loss of 20.7% in the obesity cohort at this dose, with approximately one in three participants achieving at least 25% body weight loss. A separate STEP UP T2D arm tested the same dose in people with obesity and type 2 diabetes, where mean weight loss was 14.1%.
For comparison, the currently marketed Wegovy dose (2.4 mg weekly) produced roughly 14.9% mean weight loss in the STEP-1 trial, and tirzepatide's highest dose (15 mg) produced approximately 22.5% in the SURMOUNT-1 trial. The 7.2 mg semaglutide result sits between those two benchmarks — a meaningful improvement over the existing Wegovy dose without fully matching tirzepatide at its ceiling.
A CHMP positive opinion is a recommendation; formal marketing authorisation is granted by the European Commission, typically within two months of the committee's decision. Novo Nordisk said it expects to launch Wegovy 7.2 mg across the European Union in Q3 2026.
Why it matters
The 7.2 mg dose has already been cleared in the United States and United Kingdom. EU approval would extend access to a market where obesity prevalence is rising and where the injectable Wegovy has been available at 2.4 mg since 2022. The higher dose is specifically relevant for patients who have plateaued on the standard dose and whose provider wants to step up within the same drug class.
The STEP UP trial data were presented at the European Congress on Obesity (ECO 2026) in May — the CHMP recommendation followed days later, reflecting how closely the regulatory timeline tracked the clinical readout.
For readers following the semaglutide vs tirzepatide comparison, the 7.2 mg dose slightly closes the efficacy gap. It doesn't eliminate it — tirzepatide at 15 mg still produces greater average weight loss — but patients who've responded well to semaglutide and don't want to switch drug classes now have a higher ceiling to aim for.
What to watch
The European Commission decision is expected by late July 2026. Pricing and reimbursement negotiations in individual EU member states will then determine how quickly the higher-dose pen is actually accessible for patients. Novo Nordisk has signaled aggressive capacity expansion; the supply constraints that plagued Wegovy in 2022–2024 are unlikely to be repeated at launch.
Sources
Sources